RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea

  • RedHill Biopharma Ltd RDHL has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea. 
  • Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5 million.
  • Redhill is eligible for up to $5.6 million in milestone payments and low double-digit royalties on net sales of oral opaganib in South Korea. 
  • Kukbo will receive the exclusive rights to commercialize opaganib in South Korea for COVID-19.
  • Related: RedHill Biopharma's Upamostat Shows 100% Efficacy In Non-Hospitalized COVID-19 Patients.
  • "Every day this month, we are seeing an average of almost 2000 people hospitalized due to COVID-19 in South Korea, and we desperately need medications that can effectively treat these patients," said Hyun Ha, Kukbo's CEO." 
  • The partnership with Kukbo also includes a right of the first offer for RedHill's opaganib, RHB-107 (upamostat), and Talicia for one or more of the territories of South Korea, Japan, Indonesia, Vietnam, Thailand and/or Malaysia, extended until the end of October 2022.
  • Price Action: RDHL shares are down 1.20% at $1.65 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!